Biodesix, Inc. BDSX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Biodesix, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biodesix, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biodesix, Inc.'s cash & equivalents?
- Biodesix, Inc. (BDSX) reported cash & equivalents of $25.57M in Q1 2026.
- How has Biodesix, Inc.'s cash & equivalents changed year-over-year?
- Biodesix, Inc.'s cash & equivalents increased by 45.3% year-over-year, from $17.6M to $25.57M.
- What is the long-term trend for Biodesix, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Biodesix, Inc.'s cash & equivalents has grown at a -21.1% compound annual growth rate (CAGR), from $62.13M to $18.99M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.